Publications by authors named "Mo Dimbil"

Claim this Profile
S
Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System.
Matthew S Duprey, Nada S Al-Qadheeb, Nick O'Donnell, Keith B Hoffman, Jonathan Weinstock, Mo Dimbil

Drugs Real World Outcomes· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Abril Verden, Mo Dimbil, Robert Kyle, Brian Overstreet, Keith B Hoffman

Drug Saf· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Keith B Hoffman, Mo Dimbil, Nicholas P Tatonetti, Robert F Kyle

Drug Saf· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
Keith B Hoffman, Mo Dimbil, Robert F Kyle, Nicholas P Tatonetti, Colin B Erdman

J Manag Care Spec Pharm· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS).
Keith B Hoffman, Andrea R Demakas, Mo Dimbil, Nicholas P Tatonetti, Colin B Erdman

Drug Saf· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Keith B Hoffman, Mo Dimbil, Colin B Erdman, Nicholas P Tatonetti, Brian M Overstreet

Drug Saf· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-approval adverse events of new and old anticoagulants.
Keith B Hoffman, Andrea Demakas, Colin B Erdman, Mo Dimbil

BMJ· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.
Keith B Hoffman, Andrea Demakas, Colin B Erdman, Mo Dimbil, P Murali Doraiswamy

BMJ· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Keith B Hoffman, Christina Kraus, Mo Dimbil, Beatrice A Golomb

PLoS One· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis